



Editor

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Desirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2019 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 1015** Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

S Siebert, N L Millar, I B McInnes

Recommendation

- 1019** Consensus-based recommendations for the management of juvenile localised scleroderma

F Zulian, R Culp, F Sperotto, J Anton, T Avcin, E M Baildam, C Boros, J Chaitow, T Constantin, O Kasapcopur, S Knupp Feitosa de Oliveira, C A Pilkington, R Russo, N Toplak, A van Royen, C Saad Magalhães, S J Vastert, N M Wulffraat, I Foeldvari

Criteria

- 1025** Classification criteria for autoinflammatory recurrent fevers

M Gattorno, M Hofer, S Federici, F Vanoni, F Bovis, I Aksentijevich, J Anton, J I Arostegui, K Barron, E Ben-Cherit, P A Brogan, L Cantarini, I Ceccherini, F De Benedetti, F Dedeoglu, E Demirkaya, J Frenkel, R Goldbach-Mansky, A Gul, V Hentgen, H Hoffman, T Kallinich, I Kone-Paut, J Kuemmerle-Deschner, H J Lachmann, R M Laxer, A Livneh, L Obici, S Ozen, D Rowczenio, R Russo, Y Shinar, A Simon, N Toplak, I Toutiou, Y Uziel, M van Gijn, D Foell, C Garassino, D Kastner, A Martini, M P Sormani, N Ruperto, for the Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO)

Rheumatoid arthritis

- 1033** Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

S Glatt, P C Taylor, I B McInnes, G Schett, R Landewé, D Baeten, I Ionescu, F Strimeno, M I L Watling, S Shaw

- 1041** Medications associated with fracture risk in patients with rheumatoid arthritis

G Ozen, S Pedro, F Wolfe, K Michaud

- 1048** Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

W Xie, Y Huang, S Xiao, X Sun, Y Fan, Z Zhang

- 1055** Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39

A Spiliopoulou, M Colombo, D Plant, N Nair, J Cui, M JH Coenen, K Ikari, H Yamanaka, S Saevarsdottir, L Padyukov, S L Bridges Jr., R P Kimberly, Y Okada, P L CM van Riel, G Wolbink, I E van der Horst-Bruinsma, N de Vries, P P Tak, K Ohmura, H Canhão, H-J Guchelaar, T WJ Huizinga, L A Criswell, S Raychaudhuri, M E Weinblatt, A G Wilson, X Mariette, J D Isaacs, A W Morgan, C Pitzalis, A Barton, P McKeigue

- 1062** Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling

T Motegi, Y Kochi, K Matsuda, M Kubo, K Yamamoto, Y Momozawa

Systemic lupus erythematosus

- 1070** T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis

X Liu, W Zhang, M Zhao, L Fu, L Liu, J Wu, S Luo, L Wang, Z Wang, L Lin, Y Liu, S Wang, Y Yang, L Luo, J Jiang, X Wang, Y Tan, T Li, B Zhu, Y Zhao, X Gao, Z Wan, C Huang, M Fang, Q Li, H Peng, X Liao, J Chen, F Li, G Ling, H Zhao, H Luo, Z Xiang, J Liao, Y Liu, H Yin, H Long, H Wu, huanming Yang, J Wang, Q Lu

- 1079** Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity

N I Panousis, G K Bertias, H Ongen, I Gergianaki, M G Tektonidou, M Trachana, L Romano-Palumbo, D Bielser, C Howald, C Pamfil, A Favouriakis, D Kosmara, A Repa, P Sidiropoulos, E T Dermizakis, D T Boumpas

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

COPE

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator network

recycle

When you have finished with this please recycle it

- 1090** Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated



C Wu, Q Fu, Q Guo, S Chen, S Goswami, S Sun, T Li, X Cao, F Chu, Z Chen, M Liu, Y Liu, T Fu, P Hao, Y Hao, N Shen, C Bao, X Zhang

Overlap syndromes

- 1101** Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes

L Spielmann, B Nespola, F Séverac, E Andres, R Kessler, A Guffroy, V Poindron, T Martin, B Geny, J Sibilia, A Meyer

Paediatric rheumatology

- 1107** Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis

F Gohar, A McArdle, M Jones, N Callan, B Hernandez, C Kessel, M Miranda-Garcia, M Lavric, D Holzinger, C Pretzer, E Lainka, S J Vastert, S de Roock, O FitzGerald, S R Pennington, D Foell

Miscellaneous

- 1114** Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial



E Gjika, J-Y Beaulieu, K Vakalopoulos, M Gauthier, C Bouvet, A Gonzalez, V Morello, C Steiger, S Hirsiger, B A Lipsky, I Uçkay

- 1122** Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink



G Nakafero, M J Grainge, P R Myles, C D Mallen, W Zhang, M Doherty, J S Nguyen-Van-Tam, A Abhishek

- 1127** Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases



P Martin, J Ding, K Duffus, V P Gaddi, A McGovern, H Ray-Jones, A Yarwood, J Worthington, A Barton, G Orozco

Letters

- 1135** Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib



B Combe, A Balsa, P Sarzi-Puttini, H-P Tony, I de la Torre, V Rogai, F Durand, S Witt, J Zhong, M Dougados

- 1138** First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis

G Fent, K Mankia, B Erhayiem, L Hunt, J L Nam, L-A Bissell, J R J Foley, P G Chew, L E Brown, J P Greenwood, P Emery, S Plein, M H Buch

- 1140** Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus



C Wincup, M Menon, E Smith, A Schwartz, D Isenberg, E C Jury, C Mauri, The ABIRISK Consortium

- 1142** Short lymphocyte, but not granulocyte, telomere length in a subset of patients with systemic sclerosis

K Lakota, V S Hanumanthu, R Agrawal, M Carns, M Armanios, J Varga

- 1144** Association of *MUC5B* promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

N Namba, A Kawasaki, K Sada, F Hirano, S Kobayashi, H Yamada, H Furukawa, K Shimada, A Hashimoto, T Matsui, K Nagasaka, T Sugihara, A Suzuki, K Yamagata, T Sumida, S Tohma, S Homma, S Ozaki, H Hashimoto, H Makino, Y Arimura, M Harigai, N Tsuchiya, On behalf of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)

- 1146** Gout is associated with increased healthcare utilization after knee arthroplasty

J A Singh, J D Cleveland

Electronic pages

- e74** 'Not all drugs (and route) are same'

A A Zhanwar

- e75** Response to: 'Not all drugs (and routes) are same' by Zhanwar and Gandhi

P Charles, L Guillevin

- e76** Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities
P Willems, E De Langhe, R Westhovens, S Vanderschueren, D Blockmans, X Bossuyt
- e77** Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt *et al*
D S Pisetsky, D M Spencer, P E Lipsky, B H Rovin
- e78** Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis
J Zhou, Y Xiao, C Li, T Liu, W Wang
- e79** Response to: 'Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis'
M Dubreuil, Q Louie-Gao, C Peloquin, H K Choi, Y Zhang, T Neogi
- e80** Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus
F Wang, W Zhang, S Wang, W Pan, L Liu, M Wu, F Ding, H Hu, X Ding, H Wei, Y Zou, X Qian, M Wang, J Wu, J Tao, J Tan, Z Da, M Zhang, J Li, X Feng, L Sun
- e81** Response to: 'Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus' by Wang *et al*
N Müller-Calleja, K J Lackner
- e82** Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors
A Roger, M Groh, G Lorillon, C Le Pendu, J Maillet, D Arangalage, A Tazi, C Lebbe, B Baroudjian, J Delyon, the PATIO group
- e83** Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon *et al*
M Kostine, T Schaefferbeke, on behalf of the FHU-ACRONIM
- e84** Inconsistency between supplement and article?
H Babaoglu
- e85** Response to: 'Inconsistency between supplement and article?' by Babaoglu H
D van der Heijde, N de Peyrecave, T Nurminen
- e86** Comment on: 'Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors' by Giannelou *et al*: mutations in *TRNT1* result in a constitutive activation of type I interferon signalling
M-L Frémond, I Melki, S Kracker, V Bondet, D Duffy, G I Rice, Y J Crow, B Bader-Meunier
- e87** Multimodal analgesia to reduce NSAID induced myocardial Infarction
L White, G H An, R Vlok
- e88** Correction: *Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis*